Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO).
Depatux-M
EGFR
antibody drug conjugate
glioblastoma
targeted therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Jun 2021
03 Jun 2021
Historique:
received:
08
05
2021
revised:
28
05
2021
accepted:
01
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Depatuxizumab Mafodotin (Depatux-M; ABT-414) is an antibody-drug conjugate consisting of a specific antibody against activated EGFR and a cytotoxic agent with antimicrotubule activity. The INTELLANCE 2/EORTC 1410 phase 2 trial produced interesting results for the combination regimen of Depatux-M and temozolomide in EGFR-amplified glioblastoma patients at first recurrence. For the first time worldwide, our work investigated the clinical outcome and safety of this combination in a real-life population. Patients were enrolled from seven AINO (Italian Association of Neuro-Oncology) Institutions. The major inclusion criteria were: histologically confirmed diagnosis of glioblastoma, EGFR-amplified, one or more prior systemic therapies and ECOG PS ≤ 2. According to the original schedule, patients received Depatux-M 1.25 mg/kg every 2 weeks combined with temozolomide. The primary endpoints of the study were overall survival and safety. A total of 36 patients were enrolled. The median age was 57 years, ECOG PS was 0-1 in 28 patients (88%), MGMT methylated status was found in 22 (64%), 15 patients (42%) received the combined treatment as second-line therapy. The median OS was 8.04 months (95% CI, 5.3-10.7), the 12 month-OS was 37%. On univariate and multivariate analyses, the MGMT methylation status was the only factor resulting significantly associated with survival. Grade 3 ocular toxicity occurred in 11% of patients; no grade 4 ocular toxicity was reported. No death was considered to be drug-related. The study reported the first "real world" experience of Depatux-M plus temozolomide in recurrent glioblastoma patients. Encouraging clinical benefits were demonstrated, even though most patients were treated beyond second-line therapy. Overall, the results are close to those reported in the previous phase 2 trial. Toxicity was moderate and manageable.
Sections du résumé
BACKGROUND
BACKGROUND
Depatuxizumab Mafodotin (Depatux-M; ABT-414) is an antibody-drug conjugate consisting of a specific antibody against activated EGFR and a cytotoxic agent with antimicrotubule activity. The INTELLANCE 2/EORTC 1410 phase 2 trial produced interesting results for the combination regimen of Depatux-M and temozolomide in EGFR-amplified glioblastoma patients at first recurrence. For the first time worldwide, our work investigated the clinical outcome and safety of this combination in a real-life population.
MATERIALS AND METHODS
METHODS
Patients were enrolled from seven AINO (Italian Association of Neuro-Oncology) Institutions. The major inclusion criteria were: histologically confirmed diagnosis of glioblastoma, EGFR-amplified, one or more prior systemic therapies and ECOG PS ≤ 2. According to the original schedule, patients received Depatux-M 1.25 mg/kg every 2 weeks combined with temozolomide. The primary endpoints of the study were overall survival and safety.
RESULTS
RESULTS
A total of 36 patients were enrolled. The median age was 57 years, ECOG PS was 0-1 in 28 patients (88%), MGMT methylated status was found in 22 (64%), 15 patients (42%) received the combined treatment as second-line therapy. The median OS was 8.04 months (95% CI, 5.3-10.7), the 12 month-OS was 37%. On univariate and multivariate analyses, the MGMT methylation status was the only factor resulting significantly associated with survival. Grade 3 ocular toxicity occurred in 11% of patients; no grade 4 ocular toxicity was reported. No death was considered to be drug-related.
CONCLUSIONS
CONCLUSIONS
The study reported the first "real world" experience of Depatux-M plus temozolomide in recurrent glioblastoma patients. Encouraging clinical benefits were demonstrated, even though most patients were treated beyond second-line therapy. Overall, the results are close to those reported in the previous phase 2 trial. Toxicity was moderate and manageable.
Identifiants
pubmed: 34204877
pii: cancers13112773
doi: 10.3390/cancers13112773
pmc: PMC8199759
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Neuro Oncol. 2020 May 15;22(5):684-693
pubmed: 31747009
Oncologist. 2019 Apr;24(4):521-528
pubmed: 30266892
Ther Adv Med Oncol. 2020 May 27;12:1758835920907543
pubmed: 32550861
Cancers (Basel). 2020 Aug 14;12(8):
pubmed: 32823925
Neuro Oncol. 2010 Jan;12(1):95-103
pubmed: 20150372
Neuro Oncol. 2015 Mar;17(3):430-9
pubmed: 25140039
Front Oncol. 2020 Oct 14;10:593461
pubmed: 33154952
JAMA Oncol. 2020 Jul 1;6(7):1003-1010
pubmed: 32437507
Lancet Oncol. 2019 Jan;20(1):110-119
pubmed: 30522967
Neuro Oncol. 2019 Oct 9;21(10):1263-1272
pubmed: 31125418
Cancers (Basel). 2020 Dec 26;13(1):
pubmed: 33375286
J Clin Oncol. 2018 Dec 10;36(35):3477-3484
pubmed: 30351999
J Clin Oncol. 2020 Jan 1;38(1):81-99
pubmed: 31743054
Neuro Oncol. 2019 Jan 1;21(1):106-114
pubmed: 29982805
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
N Engl J Med. 2017 Nov 16;377(20):1954-1963
pubmed: 29141164
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Neurooncol Adv. 2019 Dec 09;2(1):vdz051
pubmed: 32642719
Cancers (Basel). 2020 Dec 15;12(12):
pubmed: 33333830
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1206-11
pubmed: 23182702
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Mol Cancer Ther. 2016 Apr;15(4):661-9
pubmed: 26846818